Research Article
Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment
Table 1
The clinicopathological characteristics of gastric cancer patients.
| | Characteristic | The testing group | The validation group | | Median (25th–75th percentile) or number (%) | Median (25th–75th percentile) or number (%) |
| | Gender | | | | Male | 288 (66.8) | 298 (69.1) | | Female | 143 (33.2) | 133 (30.9) | | Age (years) | | | | ≤59 | 222 (51.5) | 232 (53.8) | | >59 | 209 (48.5) | 199 (46.2) | | TNM category (AJCC, 7th) | | | | I | 66 (15.3) | 58 (13.5) | | II | 110 (25.5) | 100 (23.2) | | III | 201 (46.6) | 208 (48.3) | | IV | 54 (12.5) | 65 (15.1) | | N stage (AJCC, 7th) | | | | N0 | 130 (30.2) | 141 (32.7) | | N1 | 301 (69.8) | 290 (67.3) | | T stage (AJCC, 7th) | | | | T1 | 54 (12.5) | 40 (9.3) | | T2 | 46 (10.7) | 61 (14.2) | | T3 | 142 (32.9) | 138 (32.0) | | T4 | 189 (43.9) | 192 (44.5) | | M stage (AJCC, 7th) | | | | M0 | 366 (84.9) | 349 (81.0) | | M1 | 65 (15.1) | 82 (19.0) | | Primary tumor size (cm) | | | | <4.0 | 178 (41.3) | 171 (39.7) | | ≥4.0 | 253 (58.7) | 260 (60.3) | | Tumor location | | | | Proximal | 218 (50.6) | 239 (55.5) | | Remote | 160 (37.1) | 147 (34.1) | | Other | 53 (12.3) | 45 (10.4) | | Degree of differentiation | | | | Poorly or not differentiated | 253 (58.7) | 250 (58.0) | | Moderately differentiated | 174 (40.4) | 179 (41.5) | | Well differentiated | 4 (0.9) | 2 (0.5) | | Tests | | | | CRP | 1.78 (0.12–155.32) | 1.91 (0.12–278.56) | | ALB | 41.6 (25.1–49.1) | 41.9 (27.50–51.00) | | GLB | 27.3 (12.8–41.8) | 27.45 (16.90–42.00) | | PLT | 240.90 (88.00–869.00) | 235.00 (77.00–641.60) | | Neutrophil | 3.7 (0.7–17.1) | 3.80 (1.20–19.37) | | Lymphocyte | 1.6 (0.2–3.7) | 1.70 (0.23–3.80) |
|
|
